AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03237416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 (darolutamide)
Description: In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
Study NCT00658658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab administered by intravenous infusion
Study NCT02328235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Saturated Fat Diet
Description: Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study.
Study NCT03134118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 2400 milligram (mg)
Description: Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 3000 mg
Description: Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
Study NCT01997697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior change program
Description: behavior change program among patients with obesity
Study NCT02283957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Study NCT02283957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 2400 mg)
Description: Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 3000 mg)
Description: Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with JNJ-63623872 Dose)
Description: Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
Study NCT02745340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetate by Citrate substitution and vice versa
Description: substitution of acetate by citrate in dialysis fluid
Study NCT02745340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetate by Citrate substitution and vice versa
Description: substitution of acetate by citrate in dialysis fluid
Study NCT01094184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
Study NCT01094184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
Study NCT02658825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with Moxifloxacin)
Description: Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
Study NCT04366427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L-HBO
Description: as previously described.
Study NCT04366427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HBO
Description: as previously described.
Study NCT04366427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 30% O2
Description: as previously described
Study NCT02154165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The infants were randomized to phototherapy with either blue og turquoise light
Study NCT01283867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg tablets
Study NCT02342353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Study NCT02342353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT03941418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boulardii
Description: Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
Study NCT03941418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administered with placebo of same appearance, colour and taste once daily.
Study NCT01283867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500 mg tablets
Study NCT04342429 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton-beam Therapy for Small Cell Lung Cancer
Description: The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
Study NCT04397926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized neoantigen peptides vaccine
Description: Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
Study NCT02613702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft
Description: Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
Study NCT02613702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
Study NCT02613702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Original Free Gingival Graft technique
Description: Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
Study NCT02613702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Free Gingival Graft technique
Description: Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
Study NCT04329000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: On-demand Esomeprazole 40 mg QD
Study NCT04329000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Continuous Esomeprazole 40 mg QD
Study NCT01945268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inactivated trivalent influenza vaccine
Description: 0.5 ml dose injected intramuscularly
Study NCT01945268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.5 ml dose injected intramuscularly
Study NCT05982145 — intervention group
Intervention type: OTHER
Intervention: Individual interviews
Description: Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems
Study NCT05982145 — intervention group
Intervention type: OTHER
Intervention: Focus groups
Description: Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday
Study NCT05982145 — intervention group
Intervention type: OTHER
Intervention: Questionary and measures
Description: To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
Study NCT03635632 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CART cells
Description: Active dose levels:~C7R-GD2.CART cell without lymphodepletion (Arm A or Arm B)~Dose Level 2b = 3 x 10\^7 on day 0 and day 7~Dose Level 3b = 1 x 10\^8 on day 0 and day 7.~Day 7 dose (+- 2 days) will be omitted if patients have persistent CRS (Grade 2 or higher) experienced a DLT or for other clinical concerns at the discretion of the PI.
Study NCT04902430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Power chain and Crimpable hook for En-Masse Retraction
Description: Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew
Study NCT04902430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T- Loop
Description: Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
Study NCT04916392 — intervention group
Intervention type: DRUG
Intervention: Liposomal bupivacaine
Description: 5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
Study NCT05723744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias
Description: For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline
Study NCT01417221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study NCT03073863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Analysis
Study NCT03073863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Analysis
Study NCT02648594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hook wire CT guided
Description: The intervention consist to place a CT-guided hook wire in lung patient
Study NCT00093262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study NCT04366427 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 50% O2
Description: as previously described
Study NCT00578669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20mg once daily for 16 weeks
Study NCT00093262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02673138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canagliflozin
Description: basal interruption with canagliflozin
Study NCT02673138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: basal interruption without canagliflozin
Description: basal interruption
Study NCT04406376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Treatment of Bell's Palsy with prednisone, with or without tapering down.
Study NCT02658903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxys Catheter
Description: The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
Study NCT02658903 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Covidien Mona-Therm Foley catheter
Description: The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
Study NCT03478930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
Study NCT04644484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
Study NCT04644484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rabies Immune Globulin (HRIG)
Description: The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
Study NCT04644484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
Study NCT03390517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence angiography with indocianyne green
Description: The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
Study NCT04644484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: >=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
Study NCT01770041 — intervention group
Intervention type: OTHER
Intervention: Paracetamol (observation of routine administration)
Description: Normal administration of paracetamol as prescribed by operating surgeon
Study NCT04095468 — intervention group
Intervention type: RADIATION
Intervention: Preoperative Radio(Chemo)Therapy
Description: Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
Study NCT03478930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
Study NCT01416064 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Molindone
Description: The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
Study NCT00885846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qigong therapy
Description: For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
Study NCT00885846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
Study NCT03425877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MS Band 2
Description: Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
Study NCT00578669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: Once daily for 16 weeks
Study NCT01327144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
Study NCT01606397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally (capsule)
Study NCT01606397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally (capsule)
Study NCT01327144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciclovir
Description: Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
Study NCT03009916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cholestagel® (Colesevelam)
Description: 3750mg
Study NCT03009916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: 3750mg
Study NCT04340609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
Study NCT00613535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: Mechanical shaver will be used to remove large chondral flaps and loose fragments
Study NCT00613535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paragon T2
Description: Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
Study NCT00613535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lavage debridement
Description: Remove loose chondral fragments
Study NCT00613535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
Study NCT00613535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF- based Debridement
Description: Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
Study NCT02994940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: already included in arm/group descriptions
Study NCT04438226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical approach
Description: The surgical approach of hemiarthroplasty after femoral neck fracture
Study NCT02032706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deliver therapy when the supine position is detected
Description: Application of vibrotactile feedback to the neck when the supine position is detected
Study NCT03275818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
Study NCT04754971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-education program
Description: Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
Study NCT01715363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01715363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study NCT01715363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracile